Advertisement

Follow us on Twitter @CR_AACR!

From the Current Issue

  • Chromosome 12p Amplification in Triple-Negative/<em>BRCA1-</em>Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity
    Translational Science
    Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity
    Jorge Gómez-Miragaya, Ander Díaz-Navarro, Raul Tonda, Sergi Beltran, Luis Palomero, Marta Palafox, Lacey E. Dobrolecki, Chen Huang, Suhas Vasaikar, Bing Zhang, Gerburg M. Wulf, Alejandro Collado-Sole, Eva M. Trinidad, Purificación Muñoz, Laia Paré, Aleix Prat, Alejandra Bruna, Carlos Caldas, Joaquín Arribas, María Teresa Soler-Monso, Anna Petit, Judith Balmaña, Cristina Cruz, Violeta Serra, Miguel Angel Pujana, Michael T. Lewis, Xose S. Puente and Eva González-Suárez
    Cancer Res August 15 2019 79 (16) 4258-4270; DOI:10.1158/0008-5472.CAN-18-3835

    Chr12p copy number gains indicate rapid emergence of resistance to docetaxel and increased sensitivity to carboplatin, therefore sequential docetaxel/carboplatin treatment could improve survival in TNBC/BRCA1 patients.

  • Molecular Cell Biology
    ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma
    Rohit Sachdeva, Megan Wu, Sandra Smiljanic, Oleksandra Kaskun, Kimia Ghannad-Zadeh, Angela Celebre, Keren Isaev, A. Sorana Morrissy, Jennifer Guan, Jiefei Tong, Jeffrey Chan, Taylor M. Wilson, Sayf Al-Omaishi, David G. Munoz, Peter B. Dirks, Michael F. Moran, Michael D. Taylor, Jüri Reimand and Sunit Das
    Cancer Res August 15 2019 79 (16) 4057-4071; DOI:10.1158/0008-5472.CAN-18-1357

    These findings show that the transcriptional regulator ID1 is critical for glioblastoma initiation and chemoresistance and that inhibition of ID1 enhances the effect of temozolomide, delays tumor recurrence, and prolongs survival.

  • Tumor Biology and Immunology
    Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer
    Carlotta Tacconi, Federica Ungaro, Carmen Correale, Vincenzo Arena, Luca Massimino, Michael Detmar, Antonino Spinelli, Michele Carvello, Massimiliano Mazzone, Ana I. Oliveira, Federica Rubbino, Valentina Garlatti, Salvatore Spanò, Enrico Lugli, Federico S. Colombo, Alberto Malesci, Laurent Peyrin-Biroulet, Stefania Vetrano, Silvio Danese and Silvia D’Alessio
    Cancer Res August 15 2019 79 (16) 4196-4210; DOI:10.1158/0008-5472.CAN-18-3657

    The prolymphangiogenic factor VEGFC is abundant in colorectal cancer and activates VEGFR3 present on cancer-associated macrophages and lymphatic vessels; activation of VEGFR3 signalling fosters cancer immune escape, resulting in enhanced tumor growth.

See the Table of Contents

Recent Reviews

OnlineFirst Articles

Load more
Advertisement

Back to top